A 3D bioprinting exemplar of the consequences of the regulatory requirements on customized processes.

Computer-aided 3D printing approaches to the industrial production of customized 3D functional living constructs for restoration of tissue and organ function face significant regulatory challenges. Using the manufacture of a customized, 3D-bioprinted nasal implant as a well-informed but hypothetical exemplar, we examine how these products might be regulated. Existing EU and USA regulatory frameworks do not account for the differences between 3D printing and conventional manufacturing methods or the ability to create individual customized products using mechanized rather than craft approaches. Already subject to extensive regulatory control, issues related to control of the computer-aided design to manufacture process and the associated software system chain present additional scientific and regulatory challenges for manufacturers of these complex 3D-bioprinted advanced combination products.

[1]  Shuyun Liu,et al.  The ECM-Cell Interaction of Cartilage Extracellular Matrix on Chondrocytes , 2014, BioMed research international.

[2]  J. Ciurana,et al.  Biomedical production of implants by additive electro-chemical and physical processes , 2012 .

[3]  Anthony Atala,et al.  3D bioprinting of tissues and organs , 2014, Nature Biotechnology.

[4]  Yos S. Morsi,et al.  Virtual prototyping of biomanufacturing in medical applications: Conventional manufacturing processes for three-dimensional scaffolds , 2007 .

[5]  Colleen L Flanagan,et al.  Bioresorbable scaffolds for bone tissue engineering: optimal design, fabrication, mechanical testing and scale-size effects analysis. , 2015, Medical engineering & physics.

[6]  Pablo Irarrazaval,et al.  Sensitivity analysis of geometric errors in additive manufacturing medical models. , 2015, Medical engineering & physics.

[7]  C. L. Ventola Medical Applications for 3D Printing: Current and Projected Uses. , 2014, P & T : a peer-reviewed journal for formulary management.

[8]  Jean-Philippe St-Pierre,et al.  Tissue engineering and regenerative medicine: a year in review. , 2014, Tissue engineering. Part B, Reviews.

[9]  Steven S. Oh,et al.  Considerations for tissue-engineered and regenerative medicine product development prior to clinical trials in the United States. , 2010, Tissue engineering. Part B, Reviews.

[10]  Scott J Hollister,et al.  Scaffold translation: barriers between concept and clinic. , 2011, Tissue engineering. Part B, Reviews.